CLCS (Cell Source) EV-to-EBIT: 0.00 (As of Jul. 04, 2026)

What is Cell Source EV-to-EBIT?

Cell Source CLCS -3.12% 35 EV-to-EBIT is 0.00 as of Jul. 04, 2026. GuruFocus rates CLCS with a GF Score™ of 35/100.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cell Source's Enterprise Value is $0.00 Mil. Cell Source's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-3.42 Mil. Therefore, Cell Source's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Cell Source's EV-to-EBIT or its related term are showing as below:

CLCS's EV-to-EBIT is not ranked ^*
in the Biotechnology industry.
Industry Median: 15.43
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cell Source's Enterprise Value for the quarter that ended in Dec. 2024 was $25.76 Mil. Cell Source's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-3.42 Mil. Cell Source's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -13.29%.

Cell Source (OTCPK:CLCS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cell Source's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 )	=	EBIT	/	Enterprise Value (Q: Dec. 2024 )
	=	-3.424	/	25.7583
	=	-13.29 %

Cell Source's Enterprise Value for the quarter that ended in Dec. 2024 was $25.76 Mil.
Cell Source's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source EV-to-EBIT Related Terms

Cell Source EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Cell Source's EV-to-EBIT can be seen below:

Cell Source EV-to-EBIT Chart

Cell Source Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-EBIT

Get a 7-Day Free Trial

-19.22

-12.25

-9.19

-6.45

-7.52

Cell Source Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial															-6.45	-5.53	-2.23	-5.38	0.00

CLCS vs EDSA, CTXR, ASBP: EV-to-EBIT Comparison

For the Biotechnology subindustry, Cell Source's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Source EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cell Source's EV-to-EBIT falls into.

Save Embed

35GF Score

Cell Source Inc CLCS

EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cell Source EV-to-EBIT Calculation

Cell Source's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	-3.424
	=	0.00

Cell Source's current Enterprise Value is $0.00 Mil.
Cell Source's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.42 Mil.

Frequently Asked Questions Learn more about EV-to-EBIT →

What does a EV-to-EBIT of 0.00 mean?

Cell Source (CLCS) has a EV-to-EBIT of 0.00 as of Jul. 04, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cell Source and its competitors.

Is Cell Source's EV-to-EBIT too high?

Cell Source's current EV-to-EBIT is 0.00. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.

How does Cell Source's EV-to-EBIT compare to EDSA and CTXR?

Cell Source's EV-to-EBIT of 0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 15.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EV-to-EBIT for a Biotechnology company?

The median EV-to-EBIT among Biotechnology companies is 15.43, based on 367 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EV-to-EBIT mean?

A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cell Source and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Source's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cell Source stock overvalued right now?

Cell Source (CLCS) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EV-to-EBIT calculated?

EV-to-EBIT is calculated from a company's financial statements. For Cell Source (CLCS), the current EV-to-EBIT is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Industry Healthcare Biotechnology

Comparable Companies EDSA CTXR ASBP CLRB ABP CASI SYBX LEXX THAR LGVN VRTX ASX:CSL REGN ALNY XKRX:207940 XBRU:ARGX XBRU:UCB ONC INSM XKRX:068270

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019

Website https://www.cell-source.com

Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.

35GF Score

Get the complete analysis for CLCS

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.93

Price

View CLCS Analysis

See EV-to-EBIT data for all stocks →